Clinical trial startup activities are the coordinated sequence of preparatory steps that must be completed before a research site can enroll its first patient. How well and how quickly a clinical research site executes this phase are significant levers for trial success.
The clinical trial startup process begins when a protocol is approved for testing and ends at First Patient In (FPI), the moment the first eligible study participant is enrolled and gives consent.
Beyond paperwork, this phase involves:
The startup phase is the highest-risk period in a clinical trial. Delays here have a cascading effect on timelines, budgets, and data quality throughout the entire lifecycle. For sponsors and CROs, selecting sites that can execute a startup efficiently and accurately is both a logistical and a strategic decision.
Study startup refers to program-level preparation:
This is managed primarily by the sponsor and/or CRO.
Site startup refers to the execution of those conditions at each individual research site:
Site startup is the operational responsibility of the research site itself.
Study startup ends when the conditions are ready. Site startup ends when a specific site is authorized to enroll patients.
Clinical trials move through three phases: startup, maintenance, and closeout. Understanding where startup fits helps clarify why it commands such focused attention.
|
Phase |
Key Activities |
Milestone |
|
Startup |
Feasibility evaluation, site selection, regulatory submissions, contracts, staff training, site activation |
First Patient In (FPI) |
|
Maintenance |
Enrollment, retention, data collection, monitoring, protocol amendments, safety reporting |
Last Patient Last Visit |
|
Closeout |
Final data queries, document archiving, site reconciliation, close-out visit |
Database Finalization |
Everything that happens in maintenance and closeout is shaped by the quality of startup execution.
A feasibility assessment is the structured evaluation of whether a research site can successfully execute a specific trial protocol. It’s the first and most consequential startup activity; a poor feasibility decision compounds through every step that follows.
The feasibility process typically begins when a sponsor or CRO sends a questionnaire to candidate sites. Sites evaluate against key criteria: patient population fit, staff capacity, available infrastructure, competing studies, and regulatory complexity. A well-executed assessment sets realistic enrollment projections, surfaces protocol design issues before contracts are signed, and allows sites and sponsors to align on expectations before commitments are made.
Once feasibility responses are reviewed, sponsors and CROs select sites that meet their qualification criteria. Site qualification is the formal process of verifying that a candidate site has the experience, capacity, and infrastructure to successfully conduct the protocol.
Qualification criteria typically include prior therapeutic area experience, demonstrated enrollment performance, access to a diverse patient population, technology infrastructure (CTMS, EDC, eConsent), stable and trained site staff, and established IRB relationships.
Independent sites like Remington-Davis offer agility, established community relationships, and the flexibility to adapt to protocol-specific requirements. Our Columbus, Ohio, location places us at the center of a multicultural metropolitan population, with healthcare provider relationships that support targeted outreach to underrepresented groups.
Budget and contract negotiation is consistently among the most common sources of startup delay. Misaligned expectations, unclear ownership of line items, and protracted legal review cycles can all add significant time before a single regulatory document is submitted.
The core documents in this step are the Confidentiality Agreement (CDA), the Clinical Trial Agreement (CTA), and the site budget. Best practices for compressing this phase include standardized CTA templates, early alignment meetings before drafts are exchanged, and clearly defined escalation paths when negotiations stall.
Sites with established sponsor and CRO relationships and a track record of clean financial management move through this step faster because trust is already built.
Regulatory and ethics submissions are the formal approval processes required before a site can legally enroll patients. In the United States, this centers on Institutional Review Board (IRB) review — the independent body responsible for protecting the rights and welfare of research participants.
Core submission documents include the study protocol, informed consent form (ICF), investigator brochure, principal investigator CV, GCP training certificates, site-specific forms, financial disclosure forms, and the IRB application package.
High-performing sites approach submissions strategically: running regulatory review in parallel with contract negotiation and staff onboarding rather than sequencing them. The completeness and accuracy of the initial package are the most controllable variables in IRB timelines — incomplete submissions trigger additional review cycles. Sites with standardized document templates, dedicated startup coordinators, and longstanding IRB relationships consistently achieve faster first-review approvals.
A fully approved site with an undertrained clinical research team is not yet ready to enroll patients. Staff training and site onboarding prepare every study team member to perform their specific role with accuracy and consistency.
Core training components include Good Clinical Practice (GCP) certification, protocol-specific training, EDC system training, safety reporting procedures, and formal role delegation documented in the Delegation of Authority log.
Protocol deviations — one of the most significant data quality risks in clinical research — disproportionately trace back to rushed or incomplete onboarding. Misunderstood eligibility criteria, inconsistent assessment procedures, and missed reporting windows are all preventable with rigorous, role-specific training before the first patient is consented.
Site activation is the formal milestone that closes the startup phase and authorizes enrollment. It represents the convergence of all prior startup activities: regulatory approvals secured, contracts executed, staff trained, systems ready.
The Site Initiation Visit (SIV) is the sponsor’s or CRO’s formal verification that the site is operationally ready. It covers protocol review, regulatory document verification, equipment walk-through, and enrollment process alignment. SIV completion is typically the final step before a site is cleared to screen and consent patients.
FPI should be the planned outcome of a well-sequenced site activation timeline. The recruitment infrastructure is already live. The first potential participants have already been identified. The activation milestone is a starting gun, not a starting line.
The problem: A missing investigator CV or outdated GCP certificate can trigger an IRB deficiency letter, adding weeks to the review cycle. Most document delays trace back to decentralized data management: documents collected via email, tracked in spreadsheets, and reviewed manually without a quality check before submission.
The solution: eTMF platforms provide a single, version-controlled repository for all regulatory documents. Paired with a standardized startup checklist and a dedicated coordinator, sites can eliminate the most common first-submission errors.
The problem: Negotiations that start with a blank contract and no established relationship take the longest. Without standardized templates or defined escalation paths, organizations default to slow, back-and-forth cycles.
The solution: Standardized CTA templates and early alignment meetings — held before drafts are exchanged — surface friction points in time to resolve them without legal escalation.
The problem: For multi-site studies, regulatory and ethics requirements vary significantly by country, region, and institution. Sites without prior experience in a given regulatory environment consistently underestimate the documentation requirements and review timelines they will face.
The solution: Engage local regulatory experts at the feasibility stage. Plan regulatory and ethics submissions as parallel workstreams from the outset, rather than sequencing them after a primary jurisdiction’s approval.
The problem: Training is frequently compressed when startup timelines are already under pressure. Staff are onboarded in undifferentiated group sessions, and pre-SIV knowledge assessments are skipped. These gaps surface as protocol deviations after the site goes live.
The solution: Role-specific training tracks ensure each team member receives relevant instruction. Pre-SIV assessments identify knowledge gaps before enrollment begins, not after the first deviation occurs.
The problem: Sites that treat recruiting patients as a maintenance-phase activity consistently underenroll, miss timelines, and require costly protocol amendments or site additions. The gap between activation and meaningful enrollment velocity is almost always a startup planning failure.
The solution: Recruitment infrastructure should be built in parallel with regulatory and contract activities — database queries, referral pathway activation, patient-facing materials, and diversity outreach — all before FPI.
Successful startups require clear ownership across multiple organizations. Accountability gaps, where each party assumes another is handling a task, are a leading cause of delay.
|
Stakeholder |
Key Startup Responsibilities |
Common Bottlenecks |
|
Sponsor |
Protocol finalization, feasibility planning, budget authority, regulatory strategy |
Late site engagement; unrealistic timeline expectations |
|
CRO |
Site identification, regulatory submission management, contract negotiation support, monitoring |
New site relationships; coordination overhead across sites |
|
Research Site |
Document collection, IRB submissions, staff training, recruitment infrastructure, SIV preparation |
Startup tasks distributed across coordinators with no dedicated owner |
|
IRB / Ethics Committee |
Protocol risk-benefit review and approval |
Incomplete first submissions trigger additional review cycles |
The industry writes about startup from the sponsor or CRO perspective, as a process to be managed from a distance. What that tends to miss is the operational reality at the site level, where startup is the daily work of real staff managing real documents, real IRB relationships, and a real patient database.
When evaluating sites during startup qualification, the most useful questions are operational:
Sites that answer these questions with data deliver on their startup commitments. We do.
Clinical trial startup activities are the preparatory steps required before a site can enroll its first patient. They include feasibility assessment, site selection, budget and contract negotiation, regulatory and ethics submissions, staff training, and site activation.
Study startup is the protocol-level preparation managed by the sponsor or CRO. Site startup is the site-level execution of those conditions: local IRB submissions, document collection, staff training, and recruitment readiness. Site startup ends when the site is authorized for patient enrollment.
The most common causes are budget and contract bottlenecks, incomplete regulatory submissions, slow IRB review cycles, and insufficient staff training. Communication gaps between sponsors, CROs, and sites also compound delays.
Core documents include the study protocol, ICF, investigator brochure, PI CV, GCP training certificates, IRB submission package, CTA, financial disclosure forms, and delegation of authority log. They are maintained in the site’s eISF and mirrored in the sponsor’s eTMF.
A study startup specialist is a dedicated coordinator responsible for all pre-study enrollment site activities: regulatory document tracking, IRB submissions, sponsor/CRO liaison, SIV scheduling, and training completion. Sites with a dedicated specialist consistently activate faster and with fewer protocol deviations.
CTMS platforms centralize key milestone tracking and financial oversight. eTMF systems provide auditable, version-controlled document management. Digital feasibility and eConsent tools automate repetitive tasks and reduce communication delays — together compressing startup timelines.